<DOC>
	<DOCNO>NCT00001271</DOCNO>
	<brief_summary>Patients CD22 ( + ) B-cell lymphoma treat escalate dos 192 hr infusion immunotoxin Phase I study determine dose limit toxicity evidence response .</brief_summary>
	<brief_title>A Phase I Study Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA Refractory CD22 Positive B-Cell Lymphoma</brief_title>
	<detailed_description>Patients CD22 ( + ) B-cell lymphoma treat escalate dos 192 hr infusion immunotoxin Phase I study determine dose limit toxicity evidence response .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Immunotoxins</mesh_term>
	<criteria>Patients histologic diagnosis confirm pretreatment biopsy Laboratory Pathology , NCI one follow entity : Diffuse small Lymphocytic Lymphoma ; Follicular , Small Cleaved cell Lymphoma ; Follicular , Mixed Small Cleaved Large Cell Lymphoma ; Follicular Large Cell Lymphoma ; Diffuse , Intermediately Differentiated Lymphocytic Lymphoma ; Diffuse , Small Cleaved Cell Lymphoma ; Diffuse , Mixed Small Large Cell Lymphoma ; Diffuse , Large Cell Lymphoma ; Large Cell Immunoblastic Lymphoma ; Small Noncleaved Cell Lymphoma . Presence CD22 antigen least 30 percent tumor cell . Presence objectively measurable site disease . Bone marrow positivity circulate tumor cell peripheral blood consider evaluable measurable disease . No patient purely Bcell Lymphosarcoma cell leukemia without nodal soft tissue involvement . No patient Bcell chronic lymphocytic leukemia , Bcell preBcell acute lymphocytic leukemia , hairy cell leukemia . Patients objectively measurable disease outside radiation port disease clearly progress within radiation port . HIV negative . No CNS disease . No pulmonary parenchymal disease . Pleural effusion ascites may present . Patients progression disease despite least one standard combination chemotherapy regimen . No chemotherapy least two week prior entry . Patients desire candidate autologous allogeneic bone marrow transplantation procedure . Life expectancy least 3 month Creatinine clearance great 60 cc per minute . Total bilirubin le 1.5 mg/dl . SGPT less 2 time upper limit normal . Albumin great 75 percent low limit normal . If prior treatment doxorubicin , radionuclide echocardiogram ejection fraction shall least 35 percent . Performance status 02 . Not need current radiation therapy alleviate local problem . No prior exposure murine antibody . No need current corticosteroid treatment .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2000</verification_date>
	<keyword>Antigen Modulation</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Ricin A Chain</keyword>
</DOC>